Use of PRKO mice to study the role of progesterone in mammary gland development
RC Humphreys, JP Lydon, BW O'Malley… - Journal of mammary …, 1997 - Springer
To better understand the distinct physiological roles played by progesterone and estrogen
receptors (PR amd ER) 4 as well as to study directly PR function in an in vivo context, a novel …
receptors (PR amd ER) 4 as well as to study directly PR function in an in vivo context, a novel …
Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis
RC Humphreys, M Krajewska, S Krnacik… - …, 1996 - journals.biologists.com
Ductal morphogenesis in the rodent mammary gland is characterized by the rapid
penetration of the stromal fat pad by the highly proliferative terminal endbud and sub-sequent …
penetration of the stromal fat pad by the highly proliferative terminal endbud and sub-sequent …
Transforming growth factor alpha and mouse models of human breast cancer
RC Humphreys, L Hennighausen - Oncogene, 2000 - nature.com
Transforming growth factor alpha (TGFα) is a principal molecule in the normal and neoplastic
development of the mammary gland. Binding of TGFα to the epidermal growth factor …
development of the mammary gland. Binding of TGFα to the epidermal growth factor …
Mammary gland development is mediated by both stromal and epithelial progesterone receptors
RC Humphreys, J Lydon, BW O'Malley… - Molecular …, 1997 - academic.oup.com
… ability (43), although the properties defined in these in vitro assays do not always
correspond to their effects in vivo (RC Humphreys and JM Rosen, submitted for publication). …
correspond to their effects in vivo (RC Humphreys and JM Rosen, submitted for publication). …
Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli
The transcription factor Stat3 is activated through tyrosine phosphorylation by many
cytokines and is a fundamental mediator of their signals. In the mammary gland, Stat3 activity …
cytokines and is a fundamental mediator of their signals. In the mammary gland, Stat3 activity …
Trail receptors: targets for cancer therapy
RC Humphreys, W Halpern - Advances in experimental medicine and …, 2008 - Springer
A human tumor cell’s ability to avoid the normal regulatory mechanisms of cell growth, division,
and death are the hallmarks of transformation and cancer. Numerous novel therapeutic …
and death are the hallmarks of transformation and cancer. Numerous novel therapeutic …
Phase II Trial of Mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in …
…, M Dediu, M Reck, CL Cebotaru, RC Humphreys… - Clinical lung cancer, 2014 - Elsevier
Background This phase II study examined the efficacy of mapatumumab in combination with
paclitaxel and carboplatin in patients with non–small-cell lung cancer (NSCLC). Patients …
paclitaxel and carboplatin in patients with non–small-cell lung cancer (NSCLC). Patients …
Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis
RC Humphreys, L Hennighausen - 1999 - AACR
The mammary gland undergoes extensive tissue remodeling and cell death at the end of
lactation in a process known as involution. We present evidence that the prolactin-activated …
lactation in a process known as involution. We present evidence that the prolactin-activated …
Localization and quantification of Wnt-2 gene expression in mouse mammary development
TA Bühler, TC Dale, C Kieback, RC Humphreys… - Developmental …, 1993 - Elsevier
The Wnt gene family encodes a group of proteins probably involved in cell-cell communication
during several stages of vertebrate development. More than 10 members of this family …
during several stages of vertebrate development. More than 10 members of this family …
Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers
RC Humphreys, J Kirtely, A Hewit, S Biroc, N Knudsen… - Cancer Research, 2015 - AACR
Creation of ADCs by conjugating drug linkers and toxin payloads to available native lysines
or cysteines generates ADCs with highly variable drug to antibody loading and linker …
or cysteines generates ADCs with highly variable drug to antibody loading and linker …